CD177 and cancer: HA is a biocompatible, biodegradable, and nonimmunogenic biopolymer capable of actively targeting cluster of CD44 on cell surface receptors overexpressed in many cancer cells, including TNBC (Mattheolabakis et al., 2015; Safdar et al., 2018; Wang et al., 2018; Kari et al., 2020).